Clinical Trial: Immune Response in Celiac Disease on In-vitro Gluten Challenge

Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Observational

Official Title: An In-vitro Gluten Challenge on the Immunologic Response in Celiac Disease.

Brief Summary:

The main purpose of this study is to see how cells taken from the lining of the intestine behave in the laboratory with exposure to gluten and other substances that act on the immune system. The cells lining the intestine of a person with celiac disease should be different than a person without celiac disease. The study doctors would like to see how the cells react after coming in contact with gluten and if substances that act on the immune system can prevent gluten related inflammation. Examples of these substances include steroids. The cells should produce chemicals of their own in response to the gluten. These other chemicals will be measured and the results compared between those with:

  • celiac disease that does not respond to a gluten-free diet (refractory celiac disease)
  • celiac disease which is controlled by a gluten-free diet
  • uncontrolled celiac disease (either newly diagnosed with celiac disease or not on a gluten-free diet
  • gluten-sensitivity
  • disorders other than celiac disease.

Detailed Summary:

The primary purpose of this study is to determine the effect of in-vitro introduction of gluten on inflammatory response primarily Interferon-γ and other cytokines, such as IL-15, IL-18 and IL-21, in cultures obtained from small intestinal mucosal biopsy samples of subjects who underwent upper endoscopy.

Secondary goals include comparing the inflammatory response to immunosuppressants and cytokines after exposing the cultures obtained from small intestinal mucosal biopsies taken from RCD I subjects with intestinal mucosal biopsies taken from subjects with CeD controlled on a Gluten-Free Diet (GFD), uncontrolled CeD, Gluten sensitivity and Non-celiac Controls.


Sponsor: Beth Israel Deaconess Medical Center

Current Primary Outcome: change in interferon gamma [ Time Frame: 0, 6, and 24 hours ]

in vitro culture stimulated with gluten


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • change in interleukin-15 [ Time Frame: 0, 6, and 24 hours ]
    in vitro culture stimulated with gluten
  • change in interleukin-18 [ Time Frame: 0, 6, and 24 hours ]
    in vitro culture stimulated with gluten
  • change in interleukin-21 [ Time Frame: 0, 6, and 24 hours ]
    in vitro culture stimulated with gluten


Original Secondary Outcome: Same as current

Information By: Beth Israel Deaconess Medical Center

Dates:
Date Received: July 18, 2013
Date Started: February 2013
Date Completion: December 2018
Last Updated: March 23, 2017
Last Verified: March 2017